Long-term persistance of anti-GAD and anti-IA-2 antibodies in cores of diabetes type 1 (DT1)

被引：0
|
作者：
Wilmot-Roussel, H. [1 ]
Dubois-Laforgue, D. [1 ]
Carette, C. [1 ]
Caillat-Zucman, S. [2 ]
Boitard, C. [3 ]
Timsit, J. [1 ]
机构：
[1] Grp Hosp Cochin St Vincent de Paul La Roche Guyon, Paris, France
[2] Hop Necker Enfants Malad, Immunol Lab, Paris, France
[3] Hop Hotel Dieu, Paris, France
来源：
DIABETES & METABOLISM | 2010年 / 36卷
关键词：
D O I：
10.1016/S1262-3636(10)70362-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A89 / A89
页数：1
相关论文
共 50 条
  • [21] Clinical and genetic characteristics of anti-gad positive type 2 diabetes in Japanese
    中国病理生理杂志, 2001, (08) : 69 - 69
  • [22] Clinical and genetic characteristics of anti-gad positive type 2 diabetes in Japanese
    中国病理生理杂志, 2001, (09) : 112 - 112
  • [23] No association of anti-GM1 and anti-GAD antibodies with juvenile myoclonic epilepsy:: A pilot study
    Aykutlu, E
    Baykan, B
    Gürses, C
    Gokyigit, AE
    Saruhan-Direskeneli, G
    SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2005, 14 (05): : 362 - 366
  • [24] Long-term effect of rituximab in a case with late-onset Rasmussen's encephalitis with anti-ganglioside IgGQ1b and anti-GAD antibodies positivity
    Timarova, Gabriela
    Lisa, Iveta
    Kukumberg, Peter
    NEUROENDOCRINOLOGY LETTERS, 2016, 37 (03) : 179 - 183
  • [25] Prevalence of anti-GAD and IA2 autoantibodies in a French cohort of patients with diabetes eligible for bariatric surgery
    Martin, C.
    Boudaoud, A. Ait
    Poghosyan, T.
    Zhu, J.
    Larger, E.
    Greenfield, J. R.
    Czernichow, S.
    Rives-Lange, C.
    Carette, C.
    DIABETES & METABOLISM, 2020, 46 (05) : 407 - 409
  • [26] Fulminating onset type 1 diabetes with positivity for anti-GAD antibody and elevated pancreatic exocrine enzyme concentrations
    Kahara, T
    Takamura, T
    Ando, H
    Sakurai, M
    Ota, T
    Misaki, T
    Oba, S
    Iguchi, M
    Komori, K
    Kobayashi, K
    INTERNAL MEDICINE, 2003, 42 (06) : 517 - 520
  • [27] Anti-GAD antibody-positive fulminant type 1 diabetes developed following SARS-CoV-2 vaccination
    Tomohito Izumi
    Hironobu Takahashi
    Hironori Takahashi
    Diabetology International, 2023, 14 : 422 - 426
  • [28] Auto-immune cerebellar ataxia with anti-GAD antibodies accompanied by de novo late-onset type 1 diabetes mellitus
    Bayreuther, C.
    Hieronimus, S.
    Ferrari, P.
    Thomas, P.
    Lebrun, C.
    DIABETES & METABOLISM, 2008, 34 (04) : 386 - 388
  • [29] The HLA-DR B1 polymorphism and anti-GAD antibody response in Brazilian patients with type 1 diabetes
    Rodacki, M
    Zajdenverg, L
    Tortora, RP
    Reis, F
    Milech, A
    Bencke-Goncalves, MR
    Albernaz, MS
    Oliveira, JEP
    DIABETES, 2004, 53 : A537 - A537
  • [30] Affinity purification of serum-derived anti-IA-2 autoantibodies in type 1 diabetes using a novel MBP-IA-2 fusion protein
    Mendis, Thilini
    Filipova, Barbora
    Wang, Jing Jing
    Pietropaolo, Massimo
    Jackson, Michael W.
    BIOCHEMISTRY AND BIOPHYSICS REPORTS, 2023, 33
12345